Exploring new avenues for TBK1 targeted therapy in PDAC have shown that Compound II can reduce viability in human PDAC cell lines and reduced tumor burden in a pre-clinical model of KRAS driven PDAC (p48-Cre; LSL-KrasG12D; Cdkn2alox/lox, KIC) [288]. This evidence concerns the gene KRAS and neoplasm.